These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 6142587)
1. Multiple dopamine receptors in brain and the pharmacological action of substituted benzamide drugs. Jenner P; Marsden CD Acta Psychiatr Scand Suppl; 1984; 311():109-23. PubMed ID: 6142587 [TBL] [Abstract][Full Text] [Related]
2. Studies on the mechanism of action of substituted benzamide drugs. Köhler C; Ogren SO; Fuxe K Acta Psychiatr Scand Suppl; 1984; 311():125-37. PubMed ID: 6142588 [TBL] [Abstract][Full Text] [Related]
3. Effects of remoxipride and some related new substituted salicylamides on rat brain receptors. Hall H; Sällemark M; Jerning E Acta Pharmacol Toxicol (Copenh); 1986 Jan; 58(1):61-70. PubMed ID: 2869639 [TBL] [Abstract][Full Text] [Related]
4. Potent lipophilic substituted benzamide drugs are not selective D-1 dopamine receptor antagonists in the rat. Fleminger S; van de Waterbeemd H; Rupniak NM; Reavill C; Testa B; Jenner P; Marsden CD J Pharm Pharmacol; 1983 Jun; 35(6):363-8. PubMed ID: 6135774 [TBL] [Abstract][Full Text] [Related]
10. Neuroleptic properties of cis-N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-methylaminobenzamide (YM-09151-2) with selective antidopaminergic activity. Usuda S; Nishikori K; Noshiro O; Maeno H Psychopharmacology (Berl); 1981; 73(2):103-9. PubMed ID: 6112770 [TBL] [Abstract][Full Text] [Related]
11. [Selective antidopaminergic properties of remoxiprid, a new potential antipsychotic agent]. Ogren SO; Hall H; Köhler C; Magnusson O; Florvall L Arzneimittelforschung; 1985; 35(8):1227-31. PubMed ID: 2866774 [TBL] [Abstract][Full Text] [Related]
12. The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions. Ogren SO; Hall H; Köhler C; Magnusson O; Sjöstrand SE Psychopharmacology (Berl); 1986; 90(3):287-94. PubMed ID: 2947255 [TBL] [Abstract][Full Text] [Related]
13. Definition of the in-vivo binding of [3H]spiperone in rat brain using substituted benzamide drugs. Chivers JK; Reavill C; Jenner P; Marsden CD J Pharm Pharmacol; 1989 Feb; 41(2):106-11. PubMed ID: 2568417 [TBL] [Abstract][Full Text] [Related]
14. A comparison of in vitro and in vivo dopamine receptor antagonism produced by substituted benzamide drugs. Jenner P; Elliott PN; Clow A; Reavill C; Marsden CD J Pharm Pharmacol; 1978 Jan; 30(1):46-8. PubMed ID: 22724 [No Abstract] [Full Text] [Related]
15. 2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 1. van Wijngaarden I; Kruse CG; van Hes R; van der Heyden JA; Tulp MT J Med Chem; 1987 Nov; 30(11):2099-104. PubMed ID: 2889830 [TBL] [Abstract][Full Text] [Related]
16. Chronic lead treatment induces in rat a specific and differential effect on dopamine receptors in different brain areas. Lucchi L; Memo M; Airaghi ML; Spano PF; Trabucchi M Brain Res; 1981 Jun; 213(2):397-404. PubMed ID: 7248763 [TBL] [Abstract][Full Text] [Related]
19. Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration. Clow A; Theodorou A; Jenner P; Marsden CD Eur J Pharmacol; 1980 May; 63(2-3):145-57. PubMed ID: 6103814 [TBL] [Abstract][Full Text] [Related]
20. Antistereotypic effects of dopamine D-1 and D-2 antagonists after intrastriatal injection in rats. Pharmacological and regional specificity. Arnt J Naunyn Schmiedebergs Arch Pharmacol; 1985 Aug; 330(2):97-104. PubMed ID: 2864641 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]